54Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Slovakia
Neuroscience Intelligence
Slovakia neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #44 of 50 · Data maturity A · Research score 28.0 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
7Recruiting trials
19Publications
12Institutions
Executive interpretation
Slovakia ranks #44 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Sumitomo Pharma America, Inc.40 recruiting
Boehringer Ingelheim40 recruiting
Pfizer30 recruiting
Hoffmann-La Roche30 recruiting
UCB Biopharma SRL21 recruiting
UCB Pharma20 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.20 recruiting
Newron Pharmaceuticals SPA20 recruiting
Biohaven Therapeutics Ltd.10 recruiting
Bial - Portela C S.A.10 recruiting
Disease activity
Epilepsy10trials
Parkinsons9trials
Alzheimers8trials
Schizophrenia6trials
Multiple Sclerosis4trials
Depression4trials
Migraine Headache3trials
Other Neurology2trials
Bipolar Disorder2trials
Pain Neuropathy1trials
Research institutions
Comenius University BratislavaOpenAlexlinked institution
University of Pavol Jozef ŠafárikOpenAlexlinked institution
Slovak University of Technology in BratislavaOpenAlexlinked institution
Slovak Society of CardiologyOpenAlexlinked institution
Institute of Neurobiology of the Slovak Academy of SciencesOpenAlexlinked institution
Slovak Academy of SciencesOpenAlexlinked institution
University of TrnavaOpenAlexlinked institution
Institute of Virology of the Slovak Academy of SciencesOpenAlexlinked institution
Constantine the Philosopher University in NitraOpenAlexlinked institution
Bratislava University of Economics and ManagementOpenAlexlinked institution
Clinical evidence trail
NCT07067463A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisRECRUITING
NCT07018713A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic MigraineRECRUITING
NCT06887192A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRECRUITING
NCT06701903Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety DisorderRECRUITING
NCT06681480Transcranial Magnetic Stimulation (rTMS) for Refractory Focal EpilepsyACTIVE_NOT_RECRUITING
NCT06315322A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence EpilepsyACTIVE_NOT_RECRUITING
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RECRUITING
NCT06323928A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive TreatmentsCOMPLETED
NCT05211947A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX StudyTERMINATED
NCT05066230A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)TERMINATED
NCT04846881Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)COMPLETED
Research evidence trail
PUBMEDSubjective Cognitive Complaints and Somatic Symptoms in Cognitively Healthy Older Adults - Network Analysis Perspective.2026-11-01
PUBMEDCerebrospinal fluid amino acid alterations are associated with oxidative stress and neuronal injury markers in multiple sclerosis.2026-10-14
PUBMEDAtypical Atypical MECP2-Related Rett Syndrome Presenting with Movement Disorders- Predominating Phenotype.2026-10-01
PUBMEDClinical spectrum of epilepsy in children treated at a tertiary pediatric neurology center-A hospital-based cohort study.2026-10-01
PUBMEDDerivation of a new induced pluripotent stem cell line ORIONi004-A for modelling Duchenne muscular dystrophy.2026-09-01
OPENALEXSeveral lines of antioxidant defense against oxidative stress: antioxidant enzymes, nanomaterials with multiple enzyme-mimicking activities, and low-molecular-weight antioxidants2024-03-14
OPENALEXReactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging2023-08-19
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.